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http://dxObjective: Thoracic endovascular aortic repair has emerged as an effective therapy for a variety of thoracic
aortic pathologic entities. However, endograft failure remains a concern, and its treatment is often challenging.
We examined our experience with endograft failure and its treatment by endovascular and open repair.
Methods: From January 2000 to January 2012, 680 patients underwent thoracic endovascular aortic repair at the
University of Pennsylvania, and their charts were reviewed for the late outcomes and follow-up data.
Results: Of the 680 patients, 73 underwent 80 reinterventions (11.7%) during follow-up. The indications for
index thoracic endovascular aortic repair were thoracic aortic aneurysms in 381, type A dissection with frozen
elephant trunk in 52, type B dissection in 111, hybrid arch repair in 46, traumatic transection in 37, infection in
10, penetrating atherosclerotic ulcer in 25, and others in 18. The median interval from index thoracic endovas-
cular aortic repair to reintervention was 210 days. Endograft failures included endoleak in 45, proximal aortic
events in 11, distal aortic events in 15, endograft infection in 3, and others in 6. Endovascular reintervention
(n ¼ 80) was performed in 60 patients. In 20 patients, open aortic reconstructive procedures were performed.
The overall 30-day mortality was 8.7% (7/80). During follow-up, 10 late deaths occurred. The overall survival
in all patients was 81%, 60%, and 52% at 1, 5, and 7 years, respectively. The late survival for patients after
reintervention for endograft failure was similar that for the patients who did not require reintervention (P¼ .31).
Conclusions: Reintervention for endograft failure can be performed with acceptable early outcomes. The mid-
term survival for patients requiring reintervention for endograft failure was similar to that of the patients without
endograft failure. Thus, reintervention for endograft failure should be aggressively considered when indicated.
(J Thorac Cardiovasc Surg 2013;145:S165-70)Since its introduction in the 1990s, thoracic endovascular
aortic repair (TEVAR) has emerged as an alternative surgical
therapy for thoracic aortic pathologic entities.1-4 However,
the long-term results have remained limited, and the durabil-
ity of TEVAR continues to be a concern.5 Furthermore, the
application of endograft technology has expanded to include
‘‘off-label’’ indications, such as aneurysmal disease with
marginal anatomy and landing zones, aortic dissections,
arch hybrid procedures, traumatic transection, and infection.
Endograft failure has remained a significant clinical con-
cern. The failure modes of TEVAR include endoleak, stent
fracture and migration, proximal and distal aortic degener-
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The Journal of Thoracic and Cardreintervention in these high-risk patients has been demon-
strated to be associated with significant morbidities and
mortality.7-13 We report our experience with endograft
failure and the results of our endovascular and surgical
reintervention in 680 patients during the past decade.METHODS
We performed a retrospective review of the thoracic aortic surgery clin-
ical database at the University of Pennsylvania from January 2000 to
January 2012. The University of Pennsylvania TEVAR registry is a pro-
spectively maintained perioperative database of thoracic aortic endograft
procedures. Electronic and paper charts were reviewed for preoperative pa-
tient and demographic characteristics, the clinical presentation, the indica-
tion for surgery, perioperative events and complications, and mortality.
Postoperative and late clinical outcomes were obtained from lifelong,
continual follow-up data and patient surveillance from the Penn Thoracic
Aortic Surgery clinic.
From January 2000 to January 2012, a total of 680 patients underwent
TEVAR at the University of Pennsylvania. Of these 680 patients, 73 pa-
tients underwent 80 endovascular and surgical reinterventions for endog-
raft failure during follow-up. An additional 5 patients underwent
reintervention for endograft failure. However, the index TEVAR proce-
dures had been performed at a different outside institution. These 5 patients
were excluded from the present study because of uncertainties regarding
their preoperative clinical history and the scenario of the index TEVAR.
Statistical Analysis
All continuous variables are expressed as the mean  standard devia-
tion. Univariate analysis was performed with Fisher’s exact test to compareiovascular Surgery c Volume 145, Number 3S S165
TABLE 1. Preoperative patient demographics
Panel 4 Szeto et alPatient demographics Value
At index TEVAR
Age (y) 68  13
S1Abbreviation and Acronym
TEVAR ¼ thoracic endovascular aortic repair66 The JAortic pathologic features 680
Descending thoracic aortic aneurysm 381 (56%)
Type A dissection repair with FET 52 (8%)
Acute type B dissection 77 (11%)
Chronic type B dissection 34 (5%)
Arch hybrid repairs 46 (7%)
Traumatic transection 37 (5%)
Infection (mycotic, A-B-E fistula) 10 (1%)
Penetrating atherosclerotic ulcers 25 (4%)
Other 18 (3%)
At reintervention
Age (y) 69  13
Modes of failure
Endoleak 45 (56%)
Type I 24
Type II 5
Type III 9
Multiple or unclear origin 7
Proximal aortic events 11 (14%)
Retrograde type A dissection 9
Aneurysmal degeneration 2
Distal aortic events (dissection/expansion) 15 (18%)
Multiple failure modes 4 (5%)
Endograft infection 3 (4%)
Other (carotid occlusion, stent collapse) 2 (3%)
TEVAR, Thoracic endovascular aortic repair; FET, frozen elephant trunk;
A-B-E fistula, aortobronchial, aortoesophageal fistula.categorical variables and Student’s t test to compare continuous variables.
Statistical methods were applied to compare the freedom from reinterven-
tion and late survival using Kaplan-Meier curves. Late survival data were
determined using a linkage to the national Social Security Death Index.
Probability values for long-term survival were calculated using the log-
rank test. SPSS software, version 19.0 (SPSS, Inc, Chicago, Ill) was used
for all calculations. The institutional review board at the University of
Pennsylvania approved the study and waived the need for patient consent.
RESULTS
Indications for Index TEVAR
The preoperative patient characteristics and indications
for index TEVAR are listed in Table 1. The mean patient
age at the index TEVAR was 68  13 years and at reinter-
vention was 69  13 years. A total of 680 patients under-
went TEVAR for a variety of thoracic aortic pathologic
entities. The index procedures and indications for TEVAR
included endograft repair for descending thoracic aortic an-
eurysm in 381, proximal repair with frozen elephant trunk
for acute type A aortic dissection in 52; endograft repair
for acute and chronic type B aortic dissection in 77 and
34, respectively, endograft repair for traumatic transection
in 37; arch hybrid repair for extended aneurysm disease
of the arch and thoracic aorta in 46, endograft repair for in-
fected aortic pathologic features in 10, penetrating athero-
sclerotic ulcer in 25, and others in 18. In the 10 patients
with infected aortic pathologic features as the indication
for the index TEVAR, mycotic aneurysm was seen in 4 pa-
tients, aortoesophageal fistula in 2, aortobronchial fistula in
3, and an infected aortic homograft in 1 patient.
Reintervention and Early Outcomes
Of the 680 patients treated with TEVAR, 73 patients un-
derwent 80 reinterventions (80/680, 11.7%). In 7 patients, 2
separate reintervention events were required. The modes of
endograft failure are listed in Table 1. The most common
mode of endograft failure was endoleak (n ¼ 45, 56%).
The median interval from the index TEVAR to reinterven-
tion was 210 days. The rates of reintervention according
to the indication for the index TEVAR are listed in Table 2.
Endovascular repair was undertaken in 60 patients and
open surgical repair in 20. In the 60 patients who underwent
endovascular repair, the procedures included additional
TEVAR in 50 patients, placement of a bare metal PALMAZ
stent (Cordis Corp, Miami Lakes, Fla) in the proximal land-
ing zone for endoleak in 1 patient, an arch chimney endog-
raft technique for proximal endoleak in 1 patient (Figure 1),
a distal chimney endograft technique to the superior mesen-
teric artery and right renal artery for distal endoleak in 1ournal of Thoracic and Cardiovascular Surpatient, concomitant TEVAR/endovascular aortic repair
for aneurysmal degeneration in 1 patient, branch artery
coil embolization for type II endoleak in 3 patients, proxi-
mal reballooning of an existing endograft for endoleak in
2 patients, and deployment of an Amplatz device in the
left subclavian artery for type II endoleak in 1 patient. In
the 20 patients who underwent open reintervention, the pro-
cedures included repair of retrograde type A aortic dissec-
tion in 9 patients, arch debranching with new adjunct
TEVAR for endoleak in 1 patient, bypass of a partially cov-
ered left common carotid to ascending aorta after malde-
ployment of TEVAR in 1 patient, open total arch
reconstruction for type I endoleak in 1 patient, abdominal
visceral debranching for distal endoleak and aneurysmal
degeneration in 2 patients, and distal repair of thoracoabdo-
minal aortic aneurysm, with in 4 patients and without in 2
patients, explantation of the previous endograft (Figure 2).
The overall 30-day mortality was 8.7% (7/80). The
30-day mortality according to the mode of endograft failure
is listed in Table 3. The postoperative 30-day complications
are listed in Table 4. The 30-day mortality for endovascular
and open reintervention was similar at 6.7% and 15%, re-
spectively (P ¼ .35). The causes of death are listed in
Table 5.gery c March 2013
TABLE 2. Indication for index TEVAR and reintervention rate
Index pathologic indication for TEVAR Reintervention rate (%)
All causes 80/680 (11.7%)
Descending thoracic aneurysm 46/381 (12%)
Type A dissection 13/52 (25%)
Acute type B dissection 11/77 (14%)
Chronic type B dissection 4/34 (12%)
Arch hybrid 1/46 (2%)
Traumatic transaction 2/37 (5%)
Infection (mycotic, A-B-E fistula) 2/10 (20%)
PAU 0/25 (0%)
Other 1/18 (6%)
TEVAR, Thoracic endovascular aortic repair; A-B-E fistula, aortobronchial, aortoeso-
phageal fistula; PAU, penetrating atherosclerotic ulcer.
Szeto et al Panel 4Late Outcomes
During follow-up, the overall survival for the entire group
(all patients who underwent TEVAR) was 81%, 69%,
60%, and 52% at 1, 3, 5, and 7 years, respectively. In the
entire cohort of 680 patients, the freedom from reinterven-
tion after TEVAR was 92%, 88%, and 86% at 1, 3, and 5
years, respectively. In the 73 patients who underwent 80 re-
interventions for endograft failure, 10 late deaths occurred.
The cause of late death was aorta related in 1 patient (bleed-
ing complications after visceral debranching), nonaorta re-
lated in 4 patients, and unknown in 5 patients. The late
survival for the patients after reintervention for endograft
failure was similar to that for those who did not require re-
intervention for endograft failure (P ¼ .11; Figure 3).DISCUSSION
Because large series of TEVARwith long-term follow-up
are limited, the determination of the true incidence of endog-
raft failure and the rate of reintervention remains challeng-
ing. Early experience has suggested that reintervention is
rare.8-12,14 However, accumulating data have suggested
that endograft failure is a significant concern and that
reintervention might occur at a greater frequency thanFIGURE 1. Reintervention using arch chimney technique for proximal endolea
racic endovascular aortic repair. B, Intraoperative aortogram of proximal endolea
gram of proximal extension with adjunct thoracic endovascular aortic repair an
The Journal of Thoracic and Cardanticipated.7,13 In reviewing our experience with 680
patients who underwent TEVAR during the past decade,
the rate of reintervention for endograft failure was 11.7%.
The cause of endograft failure was multifactorial and
likely a reflection of suboptimal patient selection, question-
able indications for TEVAR, and marginal anatomic and
aortic landing zones. Since the approval of the TEVAR de-
vice for aneurysmal disease in 2005, the application of this
new technology for expanded indications—including nona-
neurysmal pathologic features—has gained widespread
adoption. In some series examining patients requiring late
reintervention, the rate of ‘‘off-label’’ use of endografts
was as great as 70% for the index TEVAR.7 In our series,
44% of patients were treated with TEVAR for nonaneurys-
mal pathologic features. These indications included aortic
dissection, traumatic transection, infected aortic pathologic
features, hybrid arch repair, penetrating atherosclerotic ul-
cer, and others.
The initial indication for TEVAR is likely a major con-
tributing factor in predicting endograft failure, and our
data certainly suggest this. Of the 80 reinterventions for
endograft failure, 34 reinterventions were performed in
patients whose indication for index TEVAR was nonaneur-
ysmal descending thoracic aortic pathologic features. An
interesting group is the patients undergoing type A aortic
dissection with frozen elephant trunk in an attempt to alter
distal aortic remodeling: 13 reinterventions in 52 patients
(25%) were performed after initial repair because of subop-
timal distal aortic remodeling and persistent false lumen
patency in the stented portion of the thoracic aorta. Our
early experience has demonstrated evidence of positive
distal aortic remodeling in most patients treated with the
frozen elephant trunk. False lumen obliteration in the
stented portion of the thoracic aorta occurs in 80% of
patients, with complete thoracoabdominal false lumen
thrombosis in 17%.2 Other groups have reported similar
early results.15,16 However, the incidence of reintervention
remains relatively high, and the benefit of thesek. A, Computed tomography scan of proximal endoleak after previous tho-
k after previous thoracic endovascular aortic repair. C, Intraoperative aorto-
d left common carotid artery stent placement (arch chimney technique).
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FIGURE 2. Open conversion for infected endograft. Computed tomography scan demonstrating infected endograft with A, pseudoaneurysm with
B, peri-graft air. C, Infected thoracic aortic endograft. D, Explantation and reconstruction using aortic homograft.
TABLE 4. Complications at 30 days: open versus endovascular
reintervention
Complication
Total
(n ¼ 80)
Open
(n ¼ 20)
Endovascular
(n ¼ 60)
P
value*
30-d Mortality 7 (8.7%) 3 (15%) 4 (6.7%) .35
Panel 4 Szeto et alreinterventions remains in question. The concept of positive
distal aortic remodeling as a result of concomitant TEVAR
in the distal thoracoabdominal aorta remains to be
investigated, and long-term follow-up data are needed be-
fore definitive conclusions can be drawn.2,20
Another interesting and difficult group to manage is pa-
tients with infected aortic pathologic entities and endograft
infection. The reintervention and complication rates in this
group of patients were also relatively high. Our significantTABLE 3. Mode of failure and reintervention 30-day mortality
Failure mode 30-d Mortality (%)
Total 7/80 (8.7%)
Endoleak 2/45 (4.4%)
Proximal aortic events (retrograde type A,
aneurysmal degeneration)
2/11 (18%)
Distal aortic events (dissection, aneurysmal
degeneration)
1/15 (6.7%)
Multiple failure modes (excluding infection) 0/4 (0%)
Endograft infection 1/3 (33%)
Other (carotid occlusion, stent collapse) 1/2 (50%)
S168 The Journal of Thoracic and Cardiovascular Surmorbidity and mortality in this group of patients mirrors
the experience from other centers.11 In the 10 patients
with infected aortic pathologic features as the indexReoperation for bleeding 2 (2.5%) 1 (5%) 1 (1.7%) .43
Permanent paraplegia/
paraparesis
0 (0%) 0 (0%) 0 (0%)
Temporary paraplegia/
paraparesis
2 (2.5%) 0 (0%) 2 (3.3%) 1
Stroke 1 (1.3%) 0 (0%) 1 (1.7%) 1
Renal failure 7 (8.7%) 3 (15%) 4 (6.7%) .35
Renal failure requiring
dialysis
4 (5%) 3 (15%) 1 (1.7%) .04
Ventilation>24 h 13 (16%) 4 (20%) 9 (15%) .72
Length of stay (d) 12.2  13 20.1  19.7 9.4  8.8 .02
Data presented as n (%) or mean  standard deviation. *Fisher’s exact test for
categorical variables, Student’s t test for continuous variables.
gery c March 2013
TABLE 5. Reintervention and cause of death
Pt. No. Indication for index TEVAR Failure mode Reintervention Cause of death
1 DTA Distal aneurysmal degeneration TEVAR/chimney to SMA/renal Mesenteric ischemia
2 DTA Type I endoleak TEVAR Rupture
3 Traumatic Transection Carotid occlusion Open ascending to carotid bypass MSOF
4 DTA Retrograde type A dissection Open proximal repair with hemiarch Bleeding/biventricular failure
5 DTA Retrograde type A dissection Open proximal repair with hemiarch MSOF
6 DTA Endoleak type III TEVAR Rupture
7 DTA Endoleak/infection TEVAR Sepsis
Pt. No., Patient number; TEVAR, thoracic endovascular aortic repair; DTA, descending thoracic aortic aneurysm; SMA, superior mesenteric artery; MSOF, multisystem organ
failure.
Szeto et al Panel 4indication for TEVAR, 2 patients underwent no additional
reintervention but both succumbed to their initial infec-
tious etiology and developed late rupture due to ongoing
infection of the endograft at 3 months. Of the remaining
8 patients, 3 underwent open explantation for infection re-
currence, with an operative mortality of 33%. Infection re-
currence or death occurred in 5 of 10 patients (50%).
Infections such as mycotic aneurysm, aortobronchial fis-
tula, and aortoesophageal fistula are at high risk of late en-
dograft failure; they reflect the surgical principle that
prohibits placement of synthetic graft material in an in-
fected field. Owing to our early dismal results with cases
involving infection, our new paradigm at our institution
is to use TEVAR as bridging therapy in a planned
2-stage approach. Emergent TEVAR for patient stabiliza-
tion is performed to mitigate the deleterious effects of sep-
sis and hemorrhagic shock. Once the patient’s status has
been medically optimized, a planned second-stage open re-
pair with explantation of the endograft is performed,FIGURE 3. Kaplan-Meier survival curve of patients treated with thoracic endo
for endograft failure was similar to that for patients who did not require reinter
The Journal of Thoracic and Cardallowing more definitive open repair when the patient is
stable.
The mode of failure is also likely a major contributing
factor in predicting a poor clinical outcome. As discussed
previously, endograft infection is associated with significant
morbidity and mortality. Proximal aortic events, particu-
larly retrograde type A aortic dissection, remain another
difficult clinical scenario. Although rare in our series
(1.3%, 9/680 patients), the mortality associated with open
repair was 22% (2/9 patients). Other series have reported
a similar incidence and poor outcome.17-19 Eggebrecht
and colleagues19 recently reported their experience in Eu-
rope: retrograde type A dissection occurred in 1.33%,
with mortality of 42%. The cause of retrograde type A dis-
section is likely multifactorial. The factors associated with
its occurrence include type B dissection as the indication for
treatment, the failure to cover the tear site during endograft
treatment, aggressive oversizing, and ballooning. In using
TEVAR for expanded indications, recognition of thevascular aortic repair (TEVAR). Late survival in patients after reintervention
vention (P ¼ .11).
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Panel 4 Szeto et allimitation of these devices must be considered and appro-
priate preventive steps taken.
Although the complications were significant in selected
patients undergoing reintervention (the clinical scenario
discussed so far), our data are nevertheless encouraging
and have demonstrated that reintervention can be achieved
with acceptable morbidity and mortality in most patients,
despite their elderly age and comorbidities. Our overall
30-day mortality was 8.7%, with the incidence of stroke,
paraplegia, and renal failure at 1.3%, 2.5%, and 8.7%, re-
spectively. Paraplegia occurred in 2 patients (both in the en-
dovascular reintervention group). However, both patients
experienced only temporary spinal cord ischemia, and their
neurologic status resolved with no deficit. No instance of
permanent paraplegia developed. When comparing patients
who required open versus endovascular reintervention, no
difference was seen in the 30-day mortality (15% vs
6.7%, P ¼ .35). Open reintervention was, however, associ-
ated with a greater incidence of renal failure requiring dial-
ysis and a prolonged length of stay. The late survival for the
patients after reintervention for endograft failure was simi-
lar to the survival for patients who did not undergo reinter-
vention (no endograft failure). Our experience supports an
aggressive approach in treating endograft failure, because
the perioperative mortality was relatively low and the late
outcomes after reintervention were promising.
The limitation of the present study was that it was a retro-
spective review of the experience at a single center. Further-
more, this was a heterogeneous population of patients with
different characteristics and indications for TEVAR. Fur-
thermore, what was sobering was that the late survival, de-
spite an aggressive approach to reintervention, hovered
around 50%. Our late outcomes were similar to those
from other reported series, demonstrating that patients
with aortic pathologic entities have significant nonaortic
comorbidities that likely will limit their long-term survival.
CONCLUSIONS
TEVAR has emerged as an effective therapy for a variety
of thoracic aortic pathologic entities. The incidence of late
endograft failure was not insignificant, supporting the im-
portance of lifelong aortic surveillance for all patients who
have undergone TEVAR. Suboptimal patient selection, the
particular indications for treatment, and certain aortic ana-
tomic characteristics are factors contributing to endograft
failure. However, reintervention for endograft failure can
be achieved with acceptable early and late outcomes.
Just as at other centers, our center has adopted endovascu-
lar technology with great enthusiasm, especially for pa-
tients whom we believe are at extreme risk of
conventional open surgery. However, an awareness and
recognition of the limitations of the current technology
must be present, and a balance struck between overlyS170 The Journal of Thoracic and Cardiovascular Surenthusiastic embrace and prudent application with realistic
expectations.
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